Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03871257 · ClinicalTrials.gov registry record · Phase 3
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
A Phase 3 study of Low Grade Glioma and Neurofibromatosis Type 1, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
- 20
- Study locations
NCT03871257 is a Phase 3 study of Low Grade Glioma and Neurofibromatosis Type 1 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 165 participants, above the 107-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT03871257, a Phase 3 study of Low Grade Glioma and Neurofibromatosis Type 1, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Chemotherapy drugs, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine.
Conditions Studied
Interventions
- DRUG Carboplatin
- OTHER Quality-of-Life Assessment
- PROCEDURE Magnetic Resonance Imaging
- OTHER Questionnaire Administration
- DRUG Selumetinib Sulfate
Study Locations (20)
California
- Loma Linda University Medical Center - Loma Linda
- Children's Hospital Los Angeles - Los Angeles
- Kaiser Permanente-Oakland - Oakland
- Children's Hospital of Orange County - Orange
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- Rady Children's Hospital - San Diego - San Diego
- Naval Medical Center -San Diego - San Diego
- UCSF Medical Center-Mission Bay - San Francisco
Florida
- Golisano Children's Hospital of Southwest Florida - Fort Myers
- UF Health Cancer Institute - Gainesville - Gainesville
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital - Hollywood
Arizona
- Banner Children's at Desert - Mesa
- Phoenix Childrens Hospital - Phoenix
Connecticut
- Connecticut Children's Medical Center - Hartford
- Yale University - New Haven
Alabama
- Children's Hospital of Alabama - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
Delaware
- Alfred I duPont Hospital for Children - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03871257
The ClinicalTrials.gov registry entry for NCT03871257 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 107-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (54% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Low Grade Glioma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03871257 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03871257 about?
NCT03871257 is a clinical study titled "A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma". This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves...
What is the current status of trial NCT03871257?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2020-01-15. Estimated completion is 2027-12-31.
What conditions does trial NCT03871257 study?
This clinical trial studies the following conditions: Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma.
What interventions are being tested in trial NCT03871257?
The interventions under investigation include: Carboplatin (DRUG), Quality-of-Life Assessment (OTHER), Magnetic Resonance Imaging (PROCEDURE), Questionnaire Administration (OTHER), Selumetinib Sulfate (DRUG).
Who is sponsoring clinical trial NCT03871257?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03871257 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
RECRUITING · Phase 3
-
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
RECRUITING · Phase 3
-
A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
A Vaccine Trial for Low Grade Gliomas
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.